Blankinship & Foster LLC Makes New $1.01 Million Investment in Gilead Sciences, Inc. (NASDAQ:GILD)

Blankinship & Foster LLC bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 12,000 shares of the biopharmaceutical company's stock, valued at approximately $1,006,000.

A number of other large investors have also recently modified their holdings of the stock. CarsonAllaria Wealth Management Ltd. grew its holdings in shares of Gilead Sciences by 198.3% during the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 238 shares during the period. nVerses Capital LLC purchased a new stake in Gilead Sciences in the third quarter worth $25,000. Valued Wealth Advisors LLC grew its stake in Gilead Sciences by 101.9% in the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 161 shares during the period. Cedar Wealth Management LLC raised its holdings in Gilead Sciences by 51.6% in the second quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company's stock worth $32,000 after purchasing an additional 160 shares in the last quarter. Finally, Strategic Investment Solutions Inc. IL purchased a new position in Gilead Sciences during the second quarter valued at $33,000. Institutional investors own 83.67% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on GILD. JPMorgan Chase & Co. upped their target price on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock an "overweight" rating in a research report on Thursday, November 7th. Barclays upped their price objective on shares of Gilead Sciences from $84.00 to $95.00 and gave the stock an "equal weight" rating in a report on Thursday, November 7th. Wells Fargo & Company lifted their target price on shares of Gilead Sciences from $100.00 to $105.00 and gave the company an "overweight" rating in a report on Thursday, November 7th. Leerink Partners upgraded Gilead Sciences from a "market perform" rating to an "outperform" rating and upped their price target for the stock from $74.00 to $96.00 in a research note on Monday, October 21st. Finally, Mizuho raised their price objective on Gilead Sciences from $90.00 to $100.00 and gave the company an "outperform" rating in a research report on Thursday, November 21st. Twelve analysts have rated the stock with a hold rating, twelve have issued a buy rating and four have issued a strong buy rating to the stock. According to MarketBeat.com, Gilead Sciences currently has a consensus rating of "Moderate Buy" and a consensus target price of $96.43.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD remained flat at $92.38 during trading on Thursday. 5,776,163 shares of the stock traded hands, compared to its average volume of 7,066,539. The company has a 50 day simple moving average of $89.65 and a 200-day simple moving average of $79.17. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The firm has a market cap of $115.13 billion, a price-to-earnings ratio of 1,026.44, a price-to-earnings-growth ratio of 2.86 and a beta of 0.18. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $98.90.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping the consensus estimate of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The business had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. During the same period last year, the firm earned $2.29 earnings per share. The company's quarterly revenue was up 7.0% on a year-over-year basis. As a group, research analysts anticipate that Gilead Sciences, Inc. will post 4.37 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 30th. Stockholders of record on Friday, December 13th will be paid a $0.77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 3.33%. The ex-dividend date of this dividend is Friday, December 13th. Gilead Sciences's dividend payout ratio (DPR) is currently 3,422.22%.

Insider Transactions at Gilead Sciences

In related news, Director Jeffrey Bluestone sold 6,788 shares of the stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total transaction of $620,355.32. Following the completion of the sale, the director now owns 8,920 shares in the company, valued at approximately $815,198.80. This trade represents a 43.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Merdad Parsey sold 25,590 shares of the business's stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total value of $2,341,485.00. Following the completion of the transaction, the insider now directly owns 99,599 shares in the company, valued at approximately $9,113,308.50. This represents a 20.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 447,234 shares of company stock valued at $41,288,086 over the last quarter. 0.29% of the stock is currently owned by company insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.